S100A7 and neoplasm: Researchers have found that it was abnormally upregulated in esophageal squamous cell carcinoma (ESCC), which might promote tumor progression by impacting M2 macrophage infiltration and angiogenesis; thereby, S100A7 was expected to act as a therapeutic target for ESCC treatment [25].